HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bernard J Escudier Selected Research

tivozanib

10/2021Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
12/2020Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
1/2020Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Bernard J Escudier Research Topics

Disease

8Renal Cell Carcinoma (Grawitz Tumor)
10/2021 - 09/2007
1Kidney Neoplasms (Kidney Cancer)
12/2020
1Neoplasms (Cancer)
12/2020
1Hypertension (High Blood Pressure)
01/2020
1Disease Progression
07/2012
1Fatigue
09/2007
1Nausea
09/2007
1Stomatitis
09/2007
1Vomiting
09/2007

Drug/Important Bio-Agent (IBA)

3tivozanibIBA
10/2021 - 01/2020
3Sorafenib (BAY 43-9006)FDA Link
10/2021 - 01/2020
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2020
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2012
1Sunitinib (Sutent)FDA Link
02/2010
1Biomarkers (Surrogate Marker)IBA
05/2009
1TOR Serine-Threonine KinasesIBA
09/2007
1Interferon-alpha (Interferon Alfa)IBA
09/2007
1temsirolimusFDA Link
09/2007

Therapy/Procedure

6Therapeutics
10/2021 - 05/2009